Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide as intravenous or oral therapy in acute promyelocytic leukemia
IRCT138710271030N4Phase 2Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in Acute promyelocytic leukaemia (APL), sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Started Jan 2009; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on IRCT138710271030N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138710271030N4.